William Blair Analysts Lower Earnings Estimates for Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Analysts at William Blair dropped their FY2018 EPS estimates for shares of Biohaven Pharmaceutical in a report released on Thursday, November 15th. William Blair analyst T. Lugo now expects that the company will post earnings of ($6.58) per share for the year, down from their prior estimate of ($5.75). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Biohaven Pharmaceutical’s Q4 2018 earnings at ($1.75) EPS, FY2019 earnings at ($6.51) EPS and FY2020 earnings at ($5.15) EPS.

A number of other analysts also recently weighed in on BHVN. Piper Jaffray Companies set a $65.00 price target on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Wednesday, November 14th. Cantor Fitzgerald cut their price target on shares of Biohaven Pharmaceutical from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday. Leerink Swann assumed coverage on shares of Biohaven Pharmaceutical in a research report on Monday, November 12th. They issued an “outperform” rating and a $50.00 price target on the stock. Oppenheimer assumed coverage on shares of Biohaven Pharmaceutical in a research report on Monday, November 12th. They issued a “buy” rating and a $63.00 price target on the stock. Finally, ValuEngine downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Monday, August 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. Biohaven Pharmaceutical has a consensus rating of “Buy” and an average target price of $49.33.

Shares of NYSE:BHVN opened at $34.92 on Monday. The company has a market capitalization of $1.41 billion, a P/E ratio of -6.98 and a beta of 1.25. Biohaven Pharmaceutical has a fifty-two week low of $16.50 and a fifty-two week high of $44.28.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its earnings results on Wednesday, November 14th. The company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.48).

A number of hedge funds have recently made changes to their positions in the business. Teachers Advisors LLC raised its holdings in Biohaven Pharmaceutical by 3.0% during the 3rd quarter. Teachers Advisors LLC now owns 56,063 shares of the company’s stock worth $2,105,000 after buying an additional 1,611 shares during the period. Swiss National Bank raised its holdings in Biohaven Pharmaceutical by 8.3% during the 3rd quarter. Swiss National Bank now owns 33,900 shares of the company’s stock worth $1,273,000 after buying an additional 2,600 shares during the period. United Services Automobile Association raised its holdings in Biohaven Pharmaceutical by 20.1% during the 2nd quarter. United Services Automobile Association now owns 16,420 shares of the company’s stock worth $649,000 after buying an additional 2,743 shares during the period. Legal & General Group Plc raised its holdings in Biohaven Pharmaceutical by 111.3% during the 1st quarter. Legal & General Group Plc now owns 5,626 shares of the company’s stock worth $145,000 after buying an additional 2,963 shares during the period. Finally, State Board of Administration of Florida Retirement System raised its holdings in Biohaven Pharmaceutical by 24.7% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,913 shares of the company’s stock worth $629,000 after buying an additional 3,150 shares during the period. Hedge funds and other institutional investors own 81.49% of the company’s stock.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

See Also: What is a Call Option?

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply